Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry

Chargin, Amanda; Morgan, Rian; Sundram, Uma; Shults, Keith; Tsay, Ellen L.; Ratti, Navneet; Patterson, Bruce K.

doi:10.1007/s00262-016-1889-3

Cited by 21 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SPC11 cell line (positive by FACS) was weakly positive only in one of the three samples (untreated, treated with gemcitabine, or treated with cisplatin/pemetrexed). This is consistent with reports showing variation among different PD-L1 antibodies (32) and that PD-L1 analysis by FACS and IHC is not fully overlapping (33).…”

Section: Chemotherapy Does Not Influence Pd-l1 Expression By Human Mesupporting

confidence: 93%

Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients

Lara

Cecconi

Hiltbrunner

et al. 2018

Clinical Cancer Research

View full text Add to dashboard Cite

Combination of immune checkpoint inhibitors with chemotherapy is under investigation for cancer treatment. We studied the rationale of such a combination for treating mesothelioma, a disease with limited treatment options. The combination of gemcitabine and immune checkpoint inhibitors outperformed immunotherapy alone with regard to tumor control and survival in a preclinical mesothelioma model; however, the addition of dexamethasone to gemcitabine and immune checkpoint inhibitors nullified the synergistic clinical response. Furthermore, treatment with gemcitabine plus anti-PD-1 resulted in an objective clinical response in two patients with mesothelioma, who were resistant to gemcitabine or anti-PD-1 as monotherapy. Thus, treatment of mesothelioma with a combination of gemcitabine with immune checkpoint inhibitors is feasible and results in synergistic clinical response compared with single treatment in the absence of steroids.

show abstract

Section: Chemotherapy Does Not Influence Pd-l1 Expression By Human Mesupporting

confidence: 93%

Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients

Lara

Cecconi

Hiltbrunner

et al. 2018

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…In previous studies, the same methodology has been used to examined the PD-L1 expression on tumor cells and immune cells isolated from nonsmall lung cancer specimens [20,21]. They showed that the results of flow cytometric detection of PD-L1 were highly concordant with the results using IHC and proposed that the differential quantification of PD-L1 on tumor cells and immune cells may allow for better prediction of response to anti-PD-1/PD-L1 antibody therapy.…”

Section: Discussionmentioning

confidence: 95%

Flow cytometry detection of cell type-specific expression of programmed death receptor ligand-1 (PD-L1) in colorectal cancer specimens

Saito

Tojo

Kumagai

et al. 2021

Heliyon

View full text Add to dashboard Cite

“…Recently, comprehensive investigations have shown that immune components contribute to tumor progression and are strong predictors in patients with solid malignancies [1–7]. The recent success of immune checkpoint inhibitors such as programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blocking antibodies in clinical trials [8–13] greatly impacted treatment strategies of several malignancies.…”

Section: Introductionmentioning

confidence: 99%

Immunological effect of local ablation combined with immunotherapy on solid malignancies

et al. 2017

View full text Add to dashboard Cite

Recent comprehensive investigations clarified that immune microenvironment surrounding tumor cells are deeply involved in tumor progression, metastasis, and response to treatment. Furthermore, several immunotherapeutic trials have achieved successful results, and the immunotherapeutic agents are available in clinical practice. To enhance their demonstrated efficacy, combination of immunotherapy and ablation has begun to emerge. Local ablations have considerable advantages as an alternative therapeutic option, especially its minimal invasiveness. In addition, local ablations have shown immune-regulatory effect in preclinical and clinical studies. Although the corresponding mechanisms are still unclear, the local ablations combined with immunotherapy have been suggested in the treatment of several solid malignancies. This article aims to review the published data on the immune-regulatory effects of local ablations including stereotactic body radiotherapy, cryoablation, radiofrequency ablation, and high-intensity-focused ultrasound. We also discuss the value of local ablations combined with immunotherapy. Local ablations have the potential to improve future patient outcomes; however, the effectiveness and safety of local ablations combined with immunotherapy should be further investigated.

show abstract

Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry

Cited by 21 publications

References 23 publications

Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients

Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients

Flow cytometry detection of cell type-specific expression of programmed death receptor ligand-1 (PD-L1) in colorectal cancer specimens

Immunological effect of local ablation combined with immunotherapy on solid malignancies

Contact Info

Product

Resources

About